Schedule 13G ownership disclosure
ACRIVON THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 004890109
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sands Capital Life Sciences Pulse Fund II, L.P.
Shares: 2,122,605.00 · Class: 6.8%
- Sands Capital Alternatives, LLC
Shares: 2,122,605.00 · Class: 6.8%
- SANDS FRANK M.
Shares: 2,122,605.00 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001875620-25-000020
- Form type
- SCHEDULE 13G/A
- Filer
- Acrivon Therapeutics, Inc.
- CIK
- CIK 1781174
- Filed
- Aug 13, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership